Roche is set to raise $1.2 billion from the sale of a US biologics manufacturing facility to Swiss contract development and manufacturing organisation (CDMO) Lonza, part of a drive to match ...

Lonza agreed to buy a manufacturing facility in the U.S. from Roche for around $1.2 billion in cash as it seeks to boost growth of its biologics division. The deal, due to close in the second half ...

We think the outlook for Lonza looks bright, especially as drug manufacturing becomes more complex with biologics and cell and gene therapies playing larger roles in the overall mix. We view Lonza ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Lonza – which generated nearly $7 billion in revenues last year from its CDMO activities, more than half of that from biologics – said the deal would expand its bioconjugates division ...

Timely toxicology material delivery is crucial for IND and CTA approvals, helping to advance drug candidates efficiently to ...

Swiss Healthcare Manufacturing Firm Lonza Bolsters Biologics Manufacturing Capacity With Roche's US Facility Acquisition For $1.2B Lonza expands biologics manufacturing capacity with acquisition ...

What Are Biologics for Rheumatoid Arthritis? Biologics are medicines made from living cells. They belong to a class of drugs called disease-modifying antirheumatic drugs (DMARDs). They treat ...

Biologics is a full-time healthcare investor who developed a passion for biotech and life saving therapies after working in the medical field for years. His trade focus is around innovative ...